Skip to Content »

Site Map

FREE Shipping: All Individuals in United States, Mexico, Central and South America & The Caribbean

Hepatitis C Direct Acting Antivirals: The New Standard of Care, An Issue of Clinics in Liver Disease

Please note that due to a system merger our fulfilment system will be down beginning September 22nd with an anticipated date to begin shipping orders October 10th. We would like to apologize for any inconvenience by offering you a special 20% discount on select products. Please use Promotional Code 12760. Click here for promotion details.

$99.00

In Stock

Hepatitis C Virus is a quickly evolving area within hepatology owing to new medical therapies. This issue, guest edited by Dr. Fred Poordad, includes the most current clinical information and treatment therapies. Expert authors have written review articles devoted to the following medical therapies: Boceprevir, Telaprevir, Protease Inhibitors in Development, NS5B Nucleoside and Non-Nucleoside Inhibitors. Review articles also address important patients like naïve- and non-responders and relapsers, the HIV co-infected patient, and the Genotype 1 and non-Genotype 1 patient.

View other titles in the “ The Clinics: Internal Medicine” Series

View all Hepatology titles

Author Information

    By Fred Poordad, Chief, Hepatology Cedars-Sinai Medical Center Los Angeles, CA

Customer Reviews

Hepatitis C Direct Acting Antivirals: The New Standard of Care, An Issue of Clinics in Liver Disease
  • Hardcover
  • Reference
  • Imprint: Saunders
  • ISBN: 978-1-4557-1107-9
  • Copyright: 2011